Biomedical Excellence for Safer Transfusion Collaborative

What it reported doing in 2025

Delbaugh rm, murphy mf, staves j, fachini rm, wendel s, hands k, bonet-bub c, kutner jm, cohn cs, cox ca, jacquot c, hasan ra, lu w, juskewitch je, raval js, rollins-raval ma, fung mk, ziman a, fermon ej, gorlin jb , peters j, dunbar nm; best formation of antid after rhogam (radar) study investigators and the biomedical excellence for safer transfusion (best) collaborative. Why do people still make anti-d over 50 years after the introduction of rho(d) immune globulin? A biomedical excellence for safer transfusion (best) collaborative study. Transfusion. 2025 mar 10. Doi: 10.1111/trf.18202. Online ahead of print.lewin a, goldman g, o'brien sf, irving do, vassallo r, tiberghien p, goto n, waters a, van de laar t, jacquot c, fachini r, germain m, & biomedical excellence for safer transfusion (best) collaborative. Blood donor characteristics and blood safety before and during the covid-19 pandemic: a best collaborative international survey. Vox sang. 2025 aug;120(8):776-783. Doi: 10.1111/vox.70055.cain l, lafrance c, morton s, latour c, girard m, tiberghien, de la taille v, datta ss, virk ms, andrews j, yahalom v, pugliese am, alba r, charlewood, kirwan s, yokoyama aph, kutner jm, nogues ea, llonch nm, daly j, irving do, schulze tj, huisman e, le poole k, vrielink h, saifee nh, pagano mb, stanworth s, & the biomedical excellence for safer transfusion collaborative. Differences in the product characteristics and clinical use of granulocytes for transfusion: the best collaborative study. Transfusion. 2025 jun;65(6):1111-1123. Https://doi.org/10.1111/trf.18263.kogler v, pagano mb, fontaine mj, azimi v, brancamp r, cataife g, covington m, delaney m, eichbaum q, jacquot c, kutner jm, lu w, saifee nh, shan h, thibodeaux sr, wali ja, yeh a, yokoyama aph, yunce m, ziman a, & the biomedical excellence for safer transfusion collaborative. Serologic characteristics and clinical significance of non-abo red blood cell antibodies in hematopoietic stem cell transplantation: the best collaborative study. Transplantation and cellular therapy. 2025 sep 23. Doi: 10.1016/j.jtct.2025.09.040. Online ahead of print.feldman tp, brandon-coatham m, kurach j, olafson c, acker j, wellington m, brown bl, & the biomedical excellence for safer transfusion (best) collaborative. Assessing red blood cell product quality with 2,3-dpg, atp and p50 assays: a best collaborative study. Vox sang. 2025 sep 23. Doi: 10.1111/vox.70117. Online ahead of print.lu w, singh u, ziman a, vassallo r, poisson jl, shih aw, raval js, grandoni j, jacquot c, germain m, dunbar nm, cohn c, & the biomedical excellence for safer transfusion (best) collaborative. Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in north america: variable practices observed from july 2016 to june 2021, the best collaborative study. Transfusion. 2025 sep 28. Doi: 10.1111/trf.18434. Online ahead of print.dunbar nm, kaufman rm, bary ks, bellairs grm, cohn cs, delettre f, ditcham s, duarte gc, ellison a, fachini r, george ce, humbrecht c, louw v, meier s, morley s, mwase m, robitaille n, rushford k, sato t, schfer r, staves j, takanashi m, tiberghien p, wendel s, wood em, ziman a, murphy mf, & the biomedical excellence for safer transfusion (best) collaborative. Abo-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: the biomedical excellence for safer transfusion collaborative study. Transfusion. 2025 sep;65(9):1621-1629. Https://doi.org/10.1111/trf.18338.aldarweesh fa, abdallah r, alvarez ip, andrews j, chlebeck tm, clower j, costelloe a, figueroa d, george c, evans m, ilstrup s, klapper eb, mueller a, peterson h, rees t, seo j, takang an, cohn cs, & the biomedical excellence for safer transfusion (best) collaborative. D-alloantibody titration assessment study: in search of a common antibody titration platforma best collaborative study. Transfusion. 2025 nov 22. Doi: 10.1111/trf.70022. Online ahead of

Financial Efficiency

• Mission deployment rate: 75%; rating input score 75
• Program expense ratio: 71.2%; rating input score 71
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Scored; rating input score 0
• Grant itemization coverage: Scored; rating input score 0
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 6 of 8 controls in place; rating input score 75
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -4.1%; rating input score 27; 27th percentile among comparable filings
• Total-asset coverage ratio: 1.95; rating input score 59; 59th percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 77; 77th percentile among comparable filings
• Officer compensation ratio: 25.5%; rating input score 14; 14th percentile among comparable filings

Growth

• Program expense growth: 24.5% per year; rating input score 100; 87th percentile among comparable filings
• Revenue growth: 5.1% per year; rating input score 100; 48th percentile among comparable filings
• Asset growth: 1.1% per year; rating input score 100; 27th percentile among comparable filings